there was an increase in satisfactory sexual intercourse episodes

A new study conducted to test the effectiveness of the female sexual dysfunction medication Intrinsa shows that overall women reported significantly improved sexual function when using it.

The study which was led by Dr. Susan Davis from Monash University in Australia was named the APHRODITE trial and was conducted at 65 different locations in Australia, North America and in the European Union and was specifically targeted at post menopausal females who suffered from a distressing loss of sexual desire and libido.

Two hundred and sixty seven of the women were given a 150 grams daily of testosterone, a further 267 were given 300 grams daily of testosterone and the last group were given a placebo. The women were administered the testosterone by the use of the Intrinsa patches made by Proctor & Gamble and in line with proper clinical testing procedure the trial was conducted in a randomised double blind format.

After 24 weeks it was clearly seen that there was an increase in satisfactory sexual intercourse episodes in the group of women who were given the larger 300g testosterone dose when compared to the placebo section. It was also noted that both groups who were given testosterone, (150g and 300g) had significantly better scores for libido and a significantly lower amount of personal distress.

The authors of the study concluded that the Intrinsa patches were increasing the number of satisfying sexual episodes and therefore could be deemed to be “clinically meaningful”. The researchers did note that there were a few side effects which included some hair thinning, acne and unwanted hair growth but that there were no changes in liver function, glucose metabolism and blood lipid levels.

The research has been published in full by the New England Journal of Medicine and will be welcomed by the makers of the female sexual dysfunction medication Intrinsa, Proctor & Gamble.